CYSLTR1 and colonic neoplasm: Furthermore, using two additional human adenocarcinoma cell lines, namely SW-480 and HT-29, we were able to strengthen the in vivo data and demonstrate the ability of the CysLT1R antagonist Montelukast to inhibit colon cancer xenograft growth.